Juergen Froehlich

Dr. Froehlich’s career spans multiple decades and covers a broad range of drug development successes. It includes strategic planning and execution of all phases of drug development and regulatory interactions across therapeutic areas such as cystic fibrosis, bronchiectasis, and hepatitis C. He has worked with biologics, peptides, small molecules and RNA therapeutics at companies including Boehringer Ingelheim, Genentech, Quintiles, Bristol-Myers-Squibb, Ipsen, Vertex, Aradigm Corporation, EnBiotix, Genevant and Spexis AG. He was instrumental in obtaining successful marketing authorizations worldwide, including the U.S., Canada, and the E.U. As Chief Medical Officer and Head of Regulatory Affairs of Aradigm Corporation, he conducted a Ph 3 trial program with a liposomal formulation of ciprofloxacin for inhalation in patients with non-cystic fibrosis bronchiectasis (NCFBE) and chronic Pseudomonas aeruginosa (PA) lung infections. Currently, as Chief Medical and Development Officer of Spexis AG, he is overseeing early and late-stage development activities for inhaled Colistin and inhaled Murepavadin to treat chronic PA lung infection, and is involved in preclinical activities, supported by the CARB-X funding, to identify novel antibiotics overcoming antibiotic resistance. He was an invited panel member at a U.S. Food and Drug Administration workshop in 2018 for inhaled antibiotics in cystic fibrosis and NCFBE.